<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03735407</url>
  </required_header>
  <id_info>
    <org_study_id>CL-SY-02-0096</org_study_id>
    <nct_id>NCT03735407</nct_id>
  </id_info>
  <brief_title>Safety,Usability and Compliance of Using C-Scan System for Providing Information on Colonic Polypoid Lesions and Masses</brief_title>
  <acronym>C-Scan</acronym>
  <official_title>Evaluation of Safety, Usability and Subject Compliance While Using Check- Cap's C-Scan System for Providing Structural Information on Colonic Polypoid Lesions and Masses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Check-Cap Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Check-Cap Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Protocol Title: Evaluation of safety, usability and subject compliance while using Check-&#xD;
      Cap's C-Scan System for providing structural information on colonic polypoid lesions and&#xD;
      masses Study Design: Prospective, Multi-center, Single-arm, safety study Purpose: To&#xD;
      demonstrate the safety of the Check-Cap C-Scan System Study Centers: Up to two (2) centers&#xD;
      located in the United States Number of Participants: 45 healthy subjects Investigational&#xD;
      Device: Check-Cap's C-Scan System comprises C-Scan Capsule, C-Scan Track and C-Scan View.&#xD;
&#xD;
      Primary Objective: To evaluate the safety of the Check-Cap C-Scan System Secondary&#xD;
      Objectives: a. To evaluate subject's compliance b. To evaluate subject's satisfaction c. To&#xD;
      collect data to improve the product's algorithm&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Overall Design: Up to 45 healthy subjects will participate in this study. Subjects to be&#xD;
      enrolled in this study are indicated and scheduled to undergo optical colonoscopy based on&#xD;
      the following symptoms or by being classified as higher than average risk based on one or&#xD;
      more of the following:&#xD;
&#xD;
        -  Surveillance - Significant findings in previous optical colonoscopy&#xD;
&#xD;
        -  Diagnostic - Polyps detected in virtual colonoscopy referred for polypectomy&#xD;
&#xD;
        -  Diagnostic - Polyps detected in previous optical colonoscopy (community setting)&#xD;
           referred for polypectomy&#xD;
&#xD;
        -  Diagnostic - Positive FIT (Fecal Immunochemical Test)&#xD;
&#xD;
        -  Diagnostic - one or more of the typical symptoms:&#xD;
&#xD;
        -  abdominal pain&#xD;
&#xD;
        -  Change in bowel habits&#xD;
&#xD;
        -  Anemia or overt bleeding in stool&#xD;
&#xD;
        -  Significant weight loss&#xD;
&#xD;
        -  First degree relatives of CRC (Colo-Rectal Cancer)subjects Alternatively, average risk&#xD;
           based on their age and demographics referred for screening for polyps&#xD;
&#xD;
      Each subject will receive a comprehensive explanation regarding the study nature. During this&#xD;
      process, and per ethical committee approval, subjects may be asked several questions (over&#xD;
      the phone) regarding their medical background for preliminary assessment of eligibility. Once&#xD;
      informed consent is obtained, a thorough evaluation of subject's eligibility will be&#xD;
      performed based on inclusion / exclusion criteria.&#xD;
&#xD;
      Eligible subjects will be required to undergo FIT procedure, per package insert instructions,&#xD;
      within pre-defined timelines. All subjects will be scheduled to undergo capsule procedure, to&#xD;
      be followed later on with optical colonoscopy procedure.&#xD;
&#xD;
      One to three days following end of C-Scan procedure the subjects will be contacted by phone&#xD;
      by the clinical coordinator to follow-up on the subject well-being. Same follow-up procedures&#xD;
      will be applied one to three days following Optical Colonoscopy procedure. Medical history&#xD;
      and concomitant medication information will be collected for all subjects.&#xD;
&#xD;
      Study Duration: The duration of study participation for each subject is expected to be&#xD;
      approximately 8-10 weeks. The total study duration across all patients is expected to be&#xD;
      approximately 6 months, dependent upon subject recruitment rate.&#xD;
&#xD;
      C-Scan Procedure: Subjects will be instructed to skip breakfast or lunch on the day of C-Scan&#xD;
      Capsule ingestion to expedite gastric passage. Liquids are allowed.&#xD;
&#xD;
      The subjects will be connected to the C-Scan Track and after successful system's activation&#xD;
      (BIT - built in test), the subject will be asked to ingest the C-Scan Capsule with some&#xD;
      water, contrast media (GE Omnipaque 350) and non-soluble fiber, in the presence of a&#xD;
      physician investigator or designee. The subject will also be provided with an RF watch. A&#xD;
      representative of the sponsor will attend the ingestion procedure, as needed to assure proper&#xD;
      activation.&#xD;
&#xD;
      Post ingestion, the subject will receive detailed instructions about the daily routine and&#xD;
      activities as well as use of the RF watch and then will be discharged home with written&#xD;
      instructions on the procedure Instructions for use (IFU), daily diary, FIT kit and capsule&#xD;
      return kit.&#xD;
&#xD;
      FIT Procedure: All subjects will be required to perform FIT procedure using [OC-Light] FIT&#xD;
      Kit prior or during the capsule procedure Capsule Return: Capsule procedure is completed upon&#xD;
      capsule excretion or system auditory indication of 'End of Procedure'. Subjects will be&#xD;
      instructed to inform the study coordinator or designee upon capsule excretion&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2019</start_date>
  <completion_date type="Actual">February 15, 2020</completion_date>
  <primary_completion_date type="Actual">January 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective, Multi-center, Single-arm, safety study</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of incidence of device and procedure related Serious Adverse Events (SAE)</measure>
    <time_frame>6 Months</time_frame>
    <description>The safety of the Check-Cap System will be evaluated by the incidence of device and procedure related Serious Adverse Events (SAE), as adjudicated by the Independent Physician Adjudicator.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Non-compliance rate of subjects (%)</measure>
    <time_frame>6 months</time_frame>
    <description>Subject compliance will be assessed by&#xD;
- Non-compliance rate throughout the study via diary completion by the subject Specific questionnaire. completed by remote subject monitoring (via telephone) The rate will be measured in a percentage scale (1-100%) Score less then 50% will be considered as a compliance failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate subject's satisfaction</measure>
    <time_frame>8 weeks</time_frame>
    <description>Subject satisfaction will be established by:&#xD;
Designated questionnaire that focuses on patient's impressions regarding tolerance and potential safety concerns, which will be provided to the subjects after the C-Scan procedure and after the colonoscopy procedure. Acceptance criteria was defined as average score &gt;3.5 (1- low satisfaction to 5- high satisfaction), which represent high satisfaction with the safety and tolerance of the C-scan system.&#xD;
Comparing patient's satisfaction with C-Scan procedure and colonoscopy procedure</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Colo-rectal Cancer</condition>
  <arm_group>
    <arm_group_label>C-Scan procedure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who are at high or at average risk for developing CRC and who are scheduled for optical colonoscopy will undergo C-Scan procedure</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>C-Scan procedure</intervention_name>
    <description>The subjects will be connected to the C-Scan Track and after successful system's activation. The subject will be asked to ingest the C-Scan Capsule with some water, contrast media The subject will be required to ingest daily dose (3 X 15 ml) of contrast media. Capsule procedure is completed upon capsule excretion.&#xD;
o Collecting procedure related data: Technical performance in normal daily routine, Segmental transit time,Procedure duration, Number of Bowel movements , Similarity between C-Scan results and colonoscopy Etc,</description>
    <arm_group_label>C-Scan procedure</arm_group_label>
    <other_name>data collection to improve the product's algorithm</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female at the age of 40-80 years' old.&#xD;
&#xD;
          2. Subject provided signed informed consent.&#xD;
&#xD;
          3. Subject is willing and able to comply with the specified study requirements and&#xD;
             follow-up evaluations, and can be contacted by telephone.&#xD;
&#xD;
          4. Subjects able and agrees to undergo colonoscopy procedure.&#xD;
&#xD;
          5. BMI &gt; 22 and â‰¤ 35.&#xD;
&#xD;
          6. Maximum body (abdominal) circumference &lt; 120 cm.&#xD;
&#xD;
          7. Has at least 3 bowel movements per week&#xD;
&#xD;
          8. A colonoscopy procedure is pre-scheduled within 60 days&#xD;
&#xD;
        Exclusion Criteria:12.3 Exclusion Criteria&#xD;
&#xD;
          1. Known history of dysphagia or other swallowing disorders.&#xD;
&#xD;
          2. History of the followings: Inflammatory Bowel Disease (IBD) including Crohn's disease&#xD;
             or Ulcerative, Colitis, Meckel's Diverticulum, Bowen Hernia, known fistulas or&#xD;
             strictures (doctors' discretion), or a history of small bowel obstruction.&#xD;
&#xD;
          3. Known motility disorders:&#xD;
&#xD;
        i. Chronic Constipation: less than 3 bowel movements/week, w/out the use of laxatives.&#xD;
&#xD;
        ii. Delayed gastric emptying. iii. Narcotic use d. Prior history of abdominal surgery that&#xD;
        might cause bowel strictures leading to capsule retention, as determined by physician&#xD;
        discretion with the exception of appendectomy, cholecystectomy and hysterectomy e. Any&#xD;
        condition believed to have an increased risk for capsule retention, strictures, bowel&#xD;
        adhesion or other obstacles to free passage of the capsule (such as intestinal tumors,&#xD;
        radiation enteritis) or incomplete colonoscopies (e.g. due to obstructions or NSAID&#xD;
        enteropathy) as determined by physician discretion.&#xD;
&#xD;
        f. Has a cardiac device (e.g. pacemaker or ICD-Implantable Cardioverter Defibrillator) or&#xD;
        any other active implanted device g. Known sensitivity to iodine, or with known kidney&#xD;
        failure. h. Known condition which precludes compliance or is contraindicated with study&#xD;
        and/or device instructions.&#xD;
&#xD;
        i. Has a Magnetic Image Resonance (MRI) procedure scheduled within 1 month j. Known&#xD;
        condition of drug abuse and/or alcoholism. k. Women who are either pregnant or nursing at&#xD;
        the time of screening (to be verified by urine or serum pregnancy test for woman of child-&#xD;
        bearing potential who are not post-menopausal or undergone surgical sterilization.&#xD;
&#xD;
        l. Concurrent participation in another clinical trial using any investigational drug or&#xD;
        device.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seth Gross</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Langone Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayoclinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>November 5, 2018</study_first_submitted>
  <study_first_submitted_qc>November 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2018</study_first_posted>
  <last_update_submitted>April 7, 2020</last_update_submitted>
  <last_update_submitted_qc>April 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

